Home / Resources / Floodgates Open for US Humira Biosimilars; Key TB Drug Can Move in India

Floodgates Open for US Humira Biosimilars; Key TB Drug Can Move in India

Article
商業化支援サービス
a group of pills and capsules

This month, the second wave of biosimilar Humira (adalimumab) sponsors ― as many as eight ― become free to launch their products. July also brings an end to Hikma’s six-month monopoly on generic competition to Jazz Pharmaceuticals’ Xyrem (sodium oxybate) 0.5g/ml oral solution in the US. Read on for additional generics highlights.

Related products
Generic Drug Manufacturing
Generics Bulletin
グローバルジェネリック医薬品、バイオシミラー、付加価値のある医薬品業界に関する他の追随を許さないニュースと分析
Regulatory compliance
Pink Sheet
製薬ニュースと規制トレンド分析のリーダー
KOL thought leader interview
In Vivo
ライフサイエンスの意思決定者のためのインタビュー、分析、重要な洞察

Related resources

A man holding a test tube
JUN 23, 2023
Article
商業化支援サービス

Generics Bulletin Explains: The Next Wave of US Humira Biosimilars

Generics Bulletin breaks down all the different Humira biosimilars players and how they are positioning themselves in such a competitive US market.

InVivo-Outlook-2023_resource-card-thumbnail
DEC 01, 2022
Report
商業化支援サービス

In Vivo Outlook 2023

Outlook 2023 includes exclusive interviews and features on topics that reach across the life sciences.

Q2 2023 Outlook Report_resource-card-thumbnail
MAR 01, 2023
Report
商業化支援サービス

Q2 2023 Pharma Outlook Report

In this report, we cover catalysts from 24 drugs, devices, diagnostics, and deals expected to occur in Q2 2023.

View All Resources